Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.

Synapses, shown as green and pink dots, represent points of communication between neurons, grown here in the laboratory from stem cells. The study found that neuronal cultures from some Alzheimer’s patients were more resilient to synapse loss after exposure to amyloid protein than others, reflecting in-life clinical symptoms.

Patient-specific stem cells are key to understanding Alzheimer’s. Researchers can turn stem cells into brain cells, which are not easily accessible from living patients, in the laboratory. One of the major challenges in studying these brain cells has been to model pathological changes characteristic of Alzheimer’s brains in the majority of patients who do not harbour genetic mutations that cause disease.

To tackle this issue, a collaborative study involving researchers from the University of Oxford and the clinical team from the Deep and Frequent Phenotyping cohort of early Alzheimer’s utilised blood samples donated by fourteen Alzheimer’s patients from multiple centres around the UK. The researchers converted the blood cells into stem cells before generating brain cells specific to each individual donor. Researchers then challenged these brain cells with toxic amyloid-beta - a key pathological protein in Alzheimer’s - to cause synapse loss. A loss of synapses – the junctions where brain cell communication takes place - is the strongest correlate for cognitive decline in Alzheimer's.

The team found that the extent of synapse loss varies among individual patient brain cell lines, and crucially, correlates with their clinical symptoms, such as cognitive decline or brain activity, given their varying levels of amyloid-beta burden in the brain.

First author, Dr Bryan Ng from Professor Richard Wade-Martins’ laboratory, said: “We are excited to have found that brain cells generated in the laboratory from individual Alzheimer’s patients reflect their clinical vulnerability to amyloid-beta. This will help us better understand mechanisms of resilience and will help in the search for new therapeutic strategies”.

The full paper ‘Neurons derived from individual early Alzheimer’s disease patients reflect their clinical vulnerability’ is available to read in Brain Communications.

Collaborating University of Oxford departments include DPAG, the Kavli Institute for Nanoscience Discovery, the Nuffield Department of Clinical Neurosciences, and the Department of Psychiatry.

Similar stories

Oxford researchers uncover how Parkinson's disease protein damages brain cells

A new study reveals a key mechanism by which the protein alpha-synuclein, the hallmark of Parkinson's disease, damages neurons (brain cells) by blocking a vital cellular gateway. The results of the study, published in Nature Communications, help to explain how the disease begins and highlights a potential new target for treatment.

New Lancet review calls for urgent action to tackle the growing global threat of encephalitis

The review highlights encephalitis as an urgent global health challenge and calling for faster diagnosis, improved treatments, and strengthened prevention strategies to reduce death and disability worldwide.

Dr Ruxandra Dafinca awarded an Alzheimer’s Society Dementia Research Leader Fellowship

Ruxandra Dafinca is one of 17 early career researchers awarded a fellowship in the 2025/2026 call for her project focused on frontotemporal dementia.

Two researchers from NDCN join global network to unravel the complexity of Parkinson’s disease

Two scientists from NDCN, Professor Andrew Sharott (Team leader) and Professor Laura Parkkinen (Co-Investigator) have been selected for multi-year grants to join the Collaborative Research Network (CRN) an international, multidisciplinary, multi-institutional network working to address high-priority research questions about Parkinson's disease.

Study shows that non-invasive ultrasound shows promise for treating Parkinson’s disease

Oxford researchers have shown for the first time that ultrasound could have similar effects on brain activity in Parkinson’s sufferers as implanted deep brain stimulation (DBS) electrodes. This opens the door to new treatment approaches that could avoid surgery.

Collaboration with the Nepal Public Health Foundation (NPHF) explores maternal health and epilepsy

A new study, co-led by Professor Arjune Sen and supported by Nuffield Department of Clinical Neurosciences, aims to improve understanding of the risk factors, care pathways and broader health and social impacts of epilepsy in Nepal.